文献速递胸部肿瘤放疗中枢神经肿瘤放疗

大分割与常规分割胸部放疗联合化疗治疗局限期小细胞肺癌的回顾性比较

Hypo- or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer.
PubMed 文献 · Radiat Oncol · 2017-03-11

本研究回顾性比较了69例接受大分割胸部放疗(HypoTRT,2.5 Gy/次,总剂量55 Gy)与101例接受常规分割胸部放疗(ConvTRT,2 Gy/次,总剂量≥56 Gy)联合依托泊苷/铂类化疗的局限期小细胞肺癌(LS-SCLC)患者的生存、失败模式及毒性。中位随访30个月,两组无进展生存(PFS)与总生存(OS)均无统计学差异,失败模式与≥3级食管炎/肺炎发生率亦相似。预防性颅脑照射(PCI)与更好的PFS和OS相关。

要点

  • 大分割胸部放疗(2.5 Gy/次,55 Gy)与常规分割(2 Gy/次,≥56 Gy)联合化疗的生存、失败模式及毒性相似。
  • 预防性颅脑照射(PCI)可显著改善2年生存率(46.1%升至70.0%)和2年PFS率(20.9%升至45.3%)。
  • 远处转移仍为主要失败模式,脑为最常见远处失败部位,其次为骨、肝和肾上腺。

核心结论

  • 大分割胸部放疗或常规分割胸部放疗联合依托泊苷/铂类化疗在局限期小细胞肺癌中显示出统计学相似的生存、治疗失败结局和毒性特征。
  • 预防性颅脑照射(PCI)与改善的无进展生存和总生存相关。

研究设计与样本

  • 共170例患者纳入分析,其中接受大分割胸部放疗者69例,接受常规分割胸部放疗者101例。
  • 常规分割胸部放疗为2 Gy/次每日,总剂量≥56 Gy;大分割胸部放疗为2.5 Gy/次每日,总剂量55 Gy。

主要发现

  • 常规分割组中位无进展生存13.7个月、中位总生存25.3个月,大分割组分别为18.2个月(p=0.991)和27.2个月(p=0.698),中位随访30个月。
  • 多因素分析显示PCI和TNM分期是无进展生存的预后因素,PCI是总生存的预后因素。
  • 两组失败模式(按局部区域复发、远处转移或两者兼有为首次复发分层)相似(p=0.693、p=0.330、p=0.572)。
  • 远处转移仍为主要失败模式,脑为最常见远处失败部位,其次为骨、肝和肾上腺。
  • 常规分割组≥3级食管炎和肺炎发生率分别为9.9%和11.9%,大分割组分别为11.6%和10.0%(p=0.815)。

关键数值与推荐

  • 预防性颅脑照射(PCI)使2年生存率从46.1%提高至70.0%,2年无进展生存率从20.9%提高至45.3%(p<0.001)。

临床怎么用

  • 对于局限期小细胞肺癌,大分割胸部放疗(2.5 Gy/次,总剂量55 Gy)可作为常规分割胸部放疗联合化疗的替代方案。
  • 预防性颅脑照射(PCI)与改善的无进展生存和总生存相关,应考虑用于适合的患者。

局限性

  • 本研究为单中心回顾性分析,可能存在选择偏倚。
  • 样本量有限(共170例),结果需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous data from our institution showed that hypofractionated thoracic radiotherapy (HypoTRT) with concurrent etoposide/platinum chemotherapy yielded favorable survival in patients with limited-stage small cell lung cancer (LS-SCLC). The present study retrospectively compared the survival outcomes, failure patterns and toxicities between groups of LS-SCLC patients treated with conventionally fractionated thoracic radiotherapy (ConvTRT) or HypoTRT combined with chemotherapy. METHODS: Medical records of LS-SCLC patients between January 2010 and December 2013 at Fudan University Shanghai Cancer Center were retrospectively reviewed. All patients treated with chemotherapy and ConvTRT (2 Gy per fraction daily, DT ≥ 56 Gy) or HypoTRT (2.5 Gy per fraction daily, DT = 55 Gy) were eligible for analysis. Progression-free survival (PFS) and overall survival (OS) were generated for different populations using the Kaplan-Meier method and compared using the log-rank test. Comparisons of failure patterns and toxicity were analyzed using the χ 2 test. RESULTS: A total of 170 patients treated with HypoTRT (n = 69) or ConvTRT (n = 101) were eligible for analysis. The median PFS and OS were 13.7 and 25.3 months, respectively, in the ConvTRT cohort, which was similar to the HypoTRT cohort (PFS 18.2 months, p = 0.991, and OS 27.2 months, p = 0.698), with a median follow-up of 30 months. Multivariate analysis revealed that PCI and TNM stage were prognostic factors for PFS and that PCI was prognostic for OS. The patterns of failure (stratified by local-regional recurrence, distant metastasis or both as first relapse) were similar between the dose cohorts (p = 0.693, p = 0.330, p = 0.572). Distant metastasis remained the main failure pattern. The brain was the most frequent remote failure site, followed by bone, liver and adrenal gland. PCI improved the 2-year survival rate from 46.1% to 70.0% and the 2-year PFS rate from 20.9% to 45.3%, respectively (p < 0.001). Grade ≥3 esophagitis and pneumonitis occurred in 9.9% and 11.9%, respectively, of the patients in the ConvTRT cohort and in 11.6% and 10.0%, respectively, of those in the HypoTRT cohort (p = 0.815). CONCLUSION: This retrospective analysis demonstrated that HypoTRT or ConvTRT combined with etoposide/platinum chemotherapy yielded statistically similar survival, treatment failure outcomes, and toxicity profiles. PCI correlated with improved PFS and OS.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zhang J, Fan M, Liu D, et al. Hypo- or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer. Radiat Oncol. 2017. PMID: 28283034. doi:10.1186/s13014-017-0788-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。